echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Egletin tartrate, a new type 1 diabetes drug of LVYE pharmaceutical, has obtained clinical approval

    Egletin tartrate, a new type 1 diabetes drug of LVYE pharmaceutical, has obtained clinical approval

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    LVYE Pharmaceutical (02186 HK) announced that the group's products under research, which are expected to be approved as class 1.1 new chemical drugs, egletin tartrate tablets have been approved by the State Food and Drug Administration (CFDA) in the first phase of clinical trials The company expects that egletin tartrate tablets will be approved for the treatment of type II diabetes Egletin tartrate tablets are dipeptidyl peptidase IV inhibitory tablets It is expected that egletin tartrate tablets will be approved for the treatment of type II diabetes The group holds the exclusive intellectual property license issued by East Asia Pharmaceutical Co., Ltd to develop and commercialize egletin tartrate tablets in China, including the exclusive right to develop egletin tartrate tablets in the name of the group for production and sale The new drug certificate and approval number issued by SFDA will apply for registration in the name of the group and be approved According to the statistics of IMS Health incorporated, the market value of China's diabetes treatment products in 2013 was about 7.8 billion yuan, with a compound annual growth rate of 23.4% from 2011 to 2013.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.